Publication: Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer
dc.contributor.buuauthor | Bayrak, Mehmet | |
dc.contributor.buuauthor | Ölmez, Ömer Fatih | |
dc.contributor.buuauthor | Kurt, Ender | |
dc.contributor.buuauthor | Çubukçu, Erdem | |
dc.contributor.buuauthor | Evrensel, Türkkan | |
dc.contributor.buuauthor | Kanat, Özkan | |
dc.contributor.buuauthor | Manavoǧlu, Osman | |
dc.contributor.department | Tıp Fakültesi | |
dc.contributor.department | Onkoloji Ana Bilim Dalı | |
dc.contributor.orcid | 0000-0002-9732-5340 | |
dc.contributor.researcherid | AAJ-1027-2021 | |
dc.contributor.scopusid | 57210190959 | |
dc.contributor.scopusid | 26435400000 | |
dc.contributor.scopusid | 7006207332 | |
dc.contributor.scopusid | 53986153800 | |
dc.contributor.scopusid | 6603942124 | |
dc.contributor.scopusid | 55881548500 | |
dc.contributor.scopusid | 6602587152 | |
dc.date.accessioned | 2022-11-21T12:28:54Z | |
dc.date.available | 2022-11-21T12:28:54Z | |
dc.date.issued | 2013-04 | |
dc.description.abstract | Overexpression of the gene c-erbB2, which encodes a receptor tyrosine kinase, has been associated with prognosis and response to therapy in several solid tumors. This study was designed to test whether c-erb-B2 overexpression can be related to prognosis of patients with metastatic gastric cancer. Between 2005 and 2010, 46 cases of metastatic gastric cancer were evaluated immunohistochemically for c-erb-B2 overexpression. Overall survival (OS) and time-to-progression (TTP) served as the main outcome measures. c-erbB2 was overexpressed in 19 (41.3 %) cases and 8 patients (17.4 %) had a c-erbB2 score of 3+ (a strong complete membrane staining observed in > 10 % of the tumor cells). c-erbB2 expression was not associated with the clinicohistological characteristics of the study participants. The mean OS was 11.48 +/- A 1.03 months, whereas the mean TTP was 8.28 +/- A 0.8 months. Compared with patients with a score of 2+ or less (n = 38), those with a c-erbB2 score of 3+ (n = 8) had both a significantly lower OS (15.55 +/- A 1.63 vs. 8.22 +/- A 0.88 months, respectively, p < 0.05) and TTP (10.72 +/- A 1.81 vs. 6.11 +/- A 0.61 months, respectively, p < 0.05). After allowance for potential confounders, Cox regression analysis identified a c-erbB2 score of 3+ as an independent predictor of both OS (hazard ratio = 1.9; 95 % confidence interval = 1.1-3.7, p < 0.05) and TTP (hazard ratio = 1.8; 95 % confidence interval = 1.1-4.1, p < 0.05). Our results suggest that c-erbB-2 overexpression may have a prognostic significance in patients with metastatic gastric cancer. | |
dc.identifier.citation | Bayrak, M. vd. (2013). "Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer". Clinical and Translational Oncology, 15(4), 307-312. | |
dc.identifier.endpage | 312 | |
dc.identifier.issn | 1699-048X | |
dc.identifier.issue | 4 | |
dc.identifier.pubmed | 22911549 | |
dc.identifier.scopus | 2-s2.0-84876494901 | |
dc.identifier.startpage | 307 | |
dc.identifier.uri | https://doi.org/10.1007/s12094-012-0921-0 | |
dc.identifier.uri | https://link.springer.com/article/10.1007/s12094-012-0921-0 | |
dc.identifier.uri | http://hdl.handle.net/11452/29523 | |
dc.identifier.volume | 15 | |
dc.identifier.wos | 000316260600009 | |
dc.indexed.scopus | Scopus | |
dc.indexed.wos | SCIE | |
dc.language.iso | en | |
dc.publisher | Springer | |
dc.relation.journal | Clinical and Translational Oncology | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Oncology | |
dc.subject | C-erbB2 | |
dc.subject | Gastric cancer | |
dc.subject | Metastasis | |
dc.subject | Immunohistochemistry | |
dc.subject | Prognosis | |
dc.subject | Expression | |
dc.subject | Trastuzumab | |
dc.subject | Breast | |
dc.subject | Her2 | |
dc.subject.emtree | Epidermal growth factor receptor 2 | |
dc.subject.emtree | Adult | |
dc.subject.emtree | Aged | |
dc.subject.emtree | Article | |
dc.subject.emtree | C erbB2 gene | |
dc.subject.emtree | Cancer growth | |
dc.subject.emtree | Cancer prognosis | |
dc.subject.emtree | Cancer survival | |
dc.subject.emtree | Clinical article | |
dc.subject.emtree | Clinical feature | |
dc.subject.emtree | Controlled study | |
dc.subject.emtree | Disease association | |
dc.subject.emtree | Female | |
dc.subject.emtree | Gene overexpression | |
dc.subject.emtree | Histopathology | |
dc.subject.emtree | Human | |
dc.subject.emtree | Human tissue | |
dc.subject.emtree | Male | |
dc.subject.emtree | Metastasis | |
dc.subject.emtree | Overall survival | |
dc.subject.emtree | Prediction | |
dc.subject.emtree | Scoring system | |
dc.subject.emtree | Stomach cancer | |
dc.subject.emtree | Time to progression | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Immunohistochemistry | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle aged | |
dc.subject.mesh | Neoplasm metastasis | |
dc.subject.mesh | Prognosis | |
dc.subject.mesh | Receptor, erbB-2 | |
dc.subject.mesh | Stomach neoplasms | |
dc.subject.mesh | Survival analysis | |
dc.subject.mesh | Tumor markers, biological | |
dc.subject.mesh | Up-regulation | |
dc.subject.mesh | Young adult | |
dc.subject.scopus | Cancer; Trastuzumab; Gastroesophageal Junction | |
dc.subject.wos | Oncology | |
dc.title | Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer | |
dc.type | Article | |
dc.wos.quartile | Q4 | |
dc.wos.quartile | Q4 | |
dspace.entity.type | Publication | |
local.contributor.department | Tıp Fakültesi/Onkoloji Ana Bilim Dalı | |
local.indexed.at | PubMed | |
local.indexed.at | WOS | |
local.indexed.at | Scopus |
Files
License bundle
1 - 1 of 1
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: